Alexander KarpAlexander Karp earned $1B in 2024

In 2024, Michael F. Mahoney earned $24.82M in total compensation at Boston Scientific, including $1.40M salary, $3.74M bonus and $19.49M in stock. Most recently acquired 260,236 shares in Feb 2025. Currently holds stock worth $179.92M. Has donated $99.61M in stock to charitable causes. Has led Boston Scientific for over 13 years.

Compensation History

Annual executive compensation data for Michael F. Mahoney, including salary, bonuses, and stock awards.

Year

2024

Total Compensation

$24.82M

Salary

$1.40M

Bonus

$3.74M

Other

$193.39K

Salary

$1.40M

Board Justification

Our philosophy is to provide appropriate competitive compensation opportunities to our executives such that actual pay outcomes are heavily influenced by achievement of Company, business and individual performance targets and objectives, which are designed to support our business strategy and create long‐term stockholder value.

Bonus

$3.74M

Board Justification

The Applicable Distribution Percentage may be further modified based on the Company’s performance against Environmental, Social and Governance (ESG) and quality goals. In the 2024 ABP, we included Adjusted OIM as a financial performance metric to help drive the Company’s continued focus on adjusted operating margin expansion, and shifted the ESG scorecard to a modifier, whereby the distribution percentage amount may be increased or decreased based on the Company’s performance towards ESG goals.

Other Compensation

$193.39K

Board Justification

Amounts in the “All Other Compensation” column are composed of the following components: Match (401(k) Plan), Aircraft, Term Life Insurance, Financial Planning, Other

Restricted Stock

$19.49M310.01K common stock

Board Justification

The amounts shown in this column represent the number of shares vested or earned multiplied by the closing price of our common stock on the vesting date.

Performance Metrics

Driving differentiated regional, business, and functional performance, Advancing category leadership, expanding into high-growth adjacencies, and enhancing our sales enabling digital capabilities, Driving global expansion, Driving profitability to fuel growth, Advancing our culture, our people capabilities, and our leadership pipeline, Progressing our ESG goals

B

Michael F. Mahoney

CEO of Boston Scientific

Education

Finance degree from the University of Iowa and an M.B.A. from Wake Forest University

Field of Expertise

Business & Management

Sector of Economy

Healthcare

Born

April 1, 1965 - 60 years ago

CEO of Boston Scientific for

13 years 1 month (Nov 2012 - Present)

Previous Experience

President of Johnson & Johnson's DePuy Orthopaedics

Holdings

Track Michael F. Mahoney's stock holdings and portfolio value over time.

Total Stock Sold

$157.28M

BSX

$157.28M

3,490,522 BSX shares

What if they kept their stock?

If Michael F. Mahoney didn't sell their stock, today they would have:
Extra BSX3,490,522 shares worth $340.40M.
This is 116.42% and $183.11M more than what they got when they sold the stock.

Charitable Transactions

BSX

1,021,385 shares

BSX

Recent Charitable Transactions

BSX

7,800 shares

BSX

Nov 26, 2024

Charity

BSX

176,245 shares

BSX

Aug 30, 2024

Charity

BSX

318,218 shares

BSX

Aug 30, 2023

Charity

BSX

365,457 shares

BSX

Sep 6, 2022

Charity

BSX

34,900 shares

BSX

Jan 1, 2022

Charity

BSX

34,965 shares

BSX

Jul 6, 2021

Charity

Insider Trading

Michael F. Mahoney's recent stock transactions, purchases, and sales filed with the SEC.

BSX

260,236 shares

BSX

Feb 11, 2025

Received

BSX

7,800 shares

BSX

Nov 26, 2024

Charity

BSX

$13.83M

BSX at $84.96/share

Nov 5, 2024

Sale

BSX

$13.78M

BSX at $84.63/share

Oct 7, 2024

Sale

BSX

$13.21M

BSX at $81.17/share

Sep 5, 2024

Sale

BSX

209,278 shares

BSX

Aug 30, 2024

Charity

BSX

176,245 shares

BSX

Aug 30, 2024

Charity

CVS

$500.29K

CVS at $54.49/share

May 2, 2024

Purchase

BSX

146,666 shares

BSX

Feb 6, 2024

Received

Rivals

Compare Michael F. Mahoney with competitor CEOs and industry peers.